Key result
Reperfusion with IGF-1 significantly improved cardiac performance (∆Psys/dia 13.8 mmHg) compared to TNF-α (6.8 mmHg) or modified Kreb's solution alone (5.1 mmHg) (P < 0.005).
Why the study?
Does insulin-like growth factor-1 (IGF-1) prevent reperfusion injury in an ex vivo murine model of myocardial ischemia/reperfusion?
Population
Ex vivo murine model of myocardial ischemia/reperfusion injury
Comparison
Perfusion with modified Kreb's solution plus… vs Perfusion with modified Kreb's solution only, or…
Design
Preclinical
Follow-up
up to 2 hours
Authors
Loading...
May support IGF-1 in preclinical reperfusion models; leaves open translation to clinical use.
Does insulin-like growth factor-1 (IGF-1) prevent reperfusion injury in an ex vivo murine model of myocardial ischemia/reperfusion?
Absolute Event Rate: 13.8% vs 5.1%
p-value: p=<0.005
In an ex vivo murine model, IGF-1 protects ischemic myocardium from reperfusion injury and improves cardiac performance, likely via mitochondria-dependent mechanisms.
Davani et al. (2003) studied Myocardial ischemia/reperfusion injury. Insulin-like growth factor-1 (IGF-1) vs. Modified Kreb's Henseleit working solution (MK) alone or MK plus TNF-alpha was evaluated on Cardiac performance (difference between ex vivo systolic and diastolic pressure, ∆Psys/dia) at 20 min of reperfusion (p=<0.005). Reperfusion with IGF-1 significantly improved cardiac performance (∆Psys/dia 13.8 mmHg) compared to TNF-α (6.8 mmHg) or modified Kreb's solution alone (5.1 mmHg) (P < 0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: